🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →
Browsing Tag

New Orleans

24 posts
Read More

Roche’s vamikibart sustains vision gains for 52 weeks as July 2027 FDA decision approaches

Genentech has reported sustained visual improvements and reduced retinal swelling through one year in two Phase III studies of vamikibart for uveitic macular edema. Approximately two-thirds of eligible patients required no retreatment after week 16, strengthening the potential treatment's durability profile. However, mixed statistical results between the pivotal trials and the absence of a direct steroid comparison remain important considerations ahead of the expected July 2027 FDA decision.